InvestorsHub Logo
Followers 55
Posts 3211
Boards Moderated 1
Alias Born 06/27/2014

Re: None

Monday, 12/28/2015 2:48:10 PM

Monday, December 28, 2015 2:48:10 PM

Post# of 20530
Recent News (12/22) - NTRR Joint Venture Begins Phase I of Testing New Topical Treatment

Dec 22, 2015
OTC Disclosure & News Service

Neutra Corp. (OTCQB: NTRR), an all-natural wellness company, is moving forward quickly with its research into a possible new line of cannabis-infused topical products. This week, the company’s joint venture partner, Oceanview Health Services Ltd., begins Phase I of its formula testing.

NTRR finalized its partnership with Vancouver-based Oceanview last week. The Canadian company gives NTRR access to government-regulated cannabis markets where demand is strong and growing for infused topicals.

“Oceanview will begin by testing out different base topical ointments that include a variety of ingredients with focus groups,” said NTRR CEO Chris Brown. “They already have some excellent cream bases to work with, and once we get the feedback we need, they’ll move on to infusing them with different cannabis strains—particularly high-CBD strains.”

The fledgling North American cannabis industry had its best year ever in 2015, and 2016 is poised to be even better. Some analysts predict that as many as six states could add cannabis referendums to their November ballots next year, with the Presidential race driving higher-than-average turnout among younger, cannabis-friendly voters.

NTRR plans to capitalize on the industry’s historic growth by potentially adding cutting-edge topical products and delivery systems to its burgeoning line of horticultural technologies. By providing new and better solutions for consumers and businesses all along the cannabis supply chain, the company hopes to keep pace with the incredible rise of the North American cannabis marketplace.

About Neutra Corp.

Neutra Corp. is a healthy lifestyle company that specializes in the development and marketing of natural wellness solutions, including cannabis-related products. By providing a variety of new technologies designed to ensure safer, more reliable access to cannabis in approved markets, Neutra Corp. plans to compete alongside GW Pharmaceuticals (NASDAQ: GWPH), Cara Therapeutics Inc. (NASDAQ: CARA) and 22nd Century Group, Inc. (NASDAQ: XXII), delivering technological advancements in the cultivation and processing of cannabis in approved markets. For investing information and performance data, please visit www.neutracorp.com.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.



View source version on businesswire.com: http://www.businesswire.com/news/home/20151222005402/en/

Copyright © 2015 Businesswire. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.